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ABSTRACT
We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin
inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety
of this regimen. Rapamycin was begun as second-line (n  9) or more than second-line (n  10) therapy. With a
median follow-up of 42 months, 16 patients were evaluable for response. Nine patients discontinued rapamycin
because of poor compliance/patient request (n  2) or an adverse event (n  7), 3 of whom were not evaluable
because of withdrawal at<1 month or noncompliance. The adverse events included serum creatinine>2.4 mg/dL
(n 4), hemolytic uremic syndrome (n 2), and relapse of malignancy (n 1). Fifteen of 16 evaluable patients had
a clinical response. Five of the 16 discontinued the drug, and 1 died of relapsed leukemia. Of the 10 patients who
continued rapamycin, 2 discontinued and 1 successfully tapered all systemic immunosuppression. Three of the 10
developed progressive cGVHD with tapering immunosuppression; all responded to resumption of prior medica-
tions. Four of the 10 patients required alternate therapy for persistent or progressive cGVHD while receiving
rapamycin; prednisone was discontinued (n 2) or tapered at the time of progressive disease (n 2). Seventeen of
19 original patients were alive. One death was due to relapsedmalignancy, and 1 was due to congestive heart failure.
In this report of rapamycin as cGVHD therapy, there is evidence of rapamycin’s efficacy. Given the significant
toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be
pursued in future cGVHD trials.
© 2005 American Society for Blood and Marrow Transplantation
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Graft-versus-host disease (GVHD) is a signiﬁcant
osttransplantation complication of allogeneic hema-
opoietic cell transplantation (HCT) that may limit
he long-term survival of the HCT recipient. Most
atients with extensive chronic GVHD (cGVHD) re-
uire prolonged immunosuppression despite an ade-
uate response to primary therapy [1-4]. The survival
f patients with cGVHD may be curtailed; those
hose ﬁrst-line therapy fails have a survival of 20% to
0%. The poorest survival is in patients with high-risk
eatures identiﬁed at the time of cGVHD diagnosis,
uch as thrombocytopenia, progressive onset of
GVHD, and extensive skin involvement [1,5,6]. The
ost commonly used and consistently effective ther- i
B&MTpy for cGVHD is corticosteroids, either in combina-
ion with other immunosuppressive agents or alone
1-3]. The toxicities and side effects of long-term
teroid therapy are well known and include glucose
ntolerance, hypertension, osteoporosis, poor wound
ealing, infections, cataracts, change in body habitus,
nd emotional lability [7]. There is a long-overdue
eed for more effective therapies, ideally with better
ide-effect proﬁles, for cGVHD.
Rapamycin (sirolimus) is a natural macrolide pro-
uced by a ﬁlamentous bacterium (Streptomyces
ygroscopicus) with immunosuppressive qualities [8].
lthough it is structurally similar to FK506 and binds
he same intracellular protein, FK binding protein, it
as a distinct mechanism of action [9]. Rapamycin
nhibits cytokine-driven signaling pathways of the T
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4ell via blockade of the mammalian target of rapamy-
in and speciﬁcally inhibits the progression of cells
rom the G1 phase to the S phase. Rapamycin has
ecome an important agent for prevention and treat-
ent of rejection in solid organ transplantation [10].
n this setting, rapamycin treatment allows for a re-
uced dose of cyclosporin (CSP) and sparing of ste-
oid therapy. In addition, rapamycin has demonstrated
ynergy with calcineurin inhibitors (CSP or FK506) in
itro and in vivo [11]. Preclinical data in allogeneic
urine bone marrow transplantation models have
hown effective prevention and treatment of GVHD,
s well as prevention of graft rejection [12-15]. We
onducted a phase II trial for patients with refractory
GVHD with the combination of calcineurin inhibi-
ors (CSP or FK506), prednisone (PSE), and rapamy-
in. The primary objective of the study was to deter-
ine the efﬁcacy of rapamycin in combination with
alcineurin inhibitors for the treatment of cGVHD.
he secondary objectives were to determine the fea-
ibility of limiting PSE as cGVHD therapy and to
eﬁne the toxicities of the rapamycin, calcineurin in-
ibitor, and PSE combination.
ETHODS
atient Eligibility
Nineteen patients with cGVHD received rapamy-
in in combination with CSP (15 patients) or FK506
4 patients) and PSE (18 patients). Patients enrolled in
his study had a diagnosis of cGVHD that required a
hange in systemic immunosuppressive therapy. The
iagnosis of cGVHD was made according to clinical
ndings consistent with cGVHD, tissue biopsy, or
oth. The diagnosis and grading of cGVHD were
ased on standard criteria and classiﬁed as de novo
without preceding acute GVHD [aGVHD]), quies-
ent (development after complete remission from
GVHD), or progressive (development from aGVHD
ithout aGVHD-free interval) onset [16]. Before be-
inning rapamycin, the patients underwent a screen-
ng evaluation that included physical examination, ap-
ropriate tissue biopsies, Schirmer tests, blood
hemistries, complete blood count with differential,
asting lipid panel, serum immunoglobulins, trough
SP or FK506 level, pulmonary function tests with
iffusion capacity, chest radiograph, and electrocar-
iogram. Patients with a serum creatinine 3 mg/dL,
n absolute neutrophil count 1000/L, or a platelet
ount 50 000/L were excluded, as were those with
ncontrolled systemic infection, unstable disease
tates (hepatic failure, ventilatory-dependent respira-
ory failure, and so on), or a Karnofsky performance
core 50. This clinical trial was approved by our
enter’s investigational review board, and all patients
ompleted and signed an informed consent. c
8atient Characteristics
Patient characteristics are summarized in Table 1.
he median age of the patients at the time of trans-
lantation was 41 years (range, 23-57 years). Seven of
he 14 myeloablative transplant patients received bone
arrow grafts, and the remaining 7 received granulo-
yte colony-stimulating factor–mobilized peripheral
lood grafts. All 5 nonmyeloablative transplant recip-
ents received granulocyte colony-stimulating factor–
obilized peripheral blood grafts. GVHD prophylaxis
as dependent on the transplantation protocol in
hich the patient was enrolled and included CSP and
ethotrexate (n  6); CSP and mycophenolate
ofetil (n  6); CSP and PSE (n  4); and CSP,
ethotrexate, and PSE (n  3). The median onset of
GVHD was 201 days (range, 100-780 days) after
ransplantation. The onset of cGVHD occurred in the
etting of tapering routine immunosuppression in 14
f the 19 patients. The median duration of cGVHD
efore rapamycin therapy was 9 months (range, 2
eeks to 9 years). Most patients received rapamycin
s second-line therapy (second line, 10 patients; third
ine, 7 patients; fourth line or more, 2 patients). All
atients had received PSE as cGVHD therapy at a
edian maximum dose of 0.36 mg/kg/d (range, 0.08-
mg/kg/d) for a median duration of 5 months (range,
-12 months) before receiving rapamycin. The patient
ho had not received PSE at the time of rapamycin
herapy had a history of sclerodermatous cGVHD for
years that had been previously treated with inter-
ittent calcineurin inhibitors, PSE, and clofazimine.
wo patients had received PSE as GVHD prophylaxis
nd had never discontinued PSE before the onset of
able 1. Patient Characteristics
Variable n
ype of transplantation
Matched sibling 16
Myeloablative/nonmyeloablative 12/4
Matched unrelated 3
Myeloablative/nonmyeloablative 2/1
iagnosis
CML 7
AML/ALL 5/3
PLL/CLL 1/1
MDS/MM 1/1
linical grade of cGVHD
Limited 2
Extensive 17
nset of cGHVD
De novo 11
Quiescent 6
Progressive 2
ML indicates chronic myelogenous leukemia; AML, acute my-
elogenous leukemia; ALL, acute lymphoblastic leukemia; PLI,
prolymphocytic leukemia; CLL, chronic lymphocytic leukemia;
MDS, myelodysplasia; MM, multiple myeloma; cGVHD,
chronic graft-versus-host disease.GVHD.
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Rapamycin and Chronic GVHD
BAll patients enrolled in the trial were assigned risk
actors that were based on the prognostic model for
GVHD patients with primary treatment failure de-
cribed by Akpek et al. [5] The risk factors include
xtensive skin involvement, progressive onset of
GVHD, platelet count 100 000/mm3, and a Karnof-
ky performance status of 50%. The cGVHD charac-
eristics for the 19 patients are summarized in Table 2.
apamycin Administration
Rapamycin was begun with a 10-mg oral loading
ose followed by a daily dose of 5 mg. The doses of
apamycin were based on reported experience in the
enal transplant literature, including ongoing random-
zed trials in renal transplant patients at the time this
rial was designed [17-20]. Although speciﬁc target
apamycin levels were not deﬁned in the original pro-
ocol, the drug was reduced to or held if 20 ng/mL.
SP or FK506 was continued, with attempts at
chieving low therapeutic whole-blood levels—100 to
00 and 5 to 15 ng/mL, respectively—before initia-
ion of rapamycin and maintaining these levels during
able 2. Pre-Sirolimus Chronic Graft-versus-Host Disease Patient Cha
atient
No.
cGVHD Site at Day 1 Rapamycin and
Status of cGVHD Prognost
1023 Scleroderma, oral, liver, stable for years Extensive
2137 Skin, oral, progressive Extensive
progres
cGVHD
1874 Skin, myositis, liver, oral, eye,
progressive
Extensive
2038 Oral, liver, progressive
1834 Oral, liver, ocular, progressive
2090 Scleroderma, vaginal, oral, progressive
1760 Scleroderma, progressive
2140 Skin, oral, ocular, progressive Extensive
2152 Liver progressive
2189 Oral, ocular, scleroderma, vaginal,
progressive
Extensive
2185 Oral, progressive
2225 Oral progressive
1578 Pulmonary, oral, liver, ocular,
progressive
1167 Skin, gut, and FTT, stable for years Progressiv
2113 Anasarca, skin, stable
281 Scleroderma, fasciitis, FTT, stable for
years
Extensive
2250 Myositis, stable
2069 Oral, skin, liver, progressive
2067 Liver, oral, scleroderma, ocular,
progressive
Extensive
GVHD indicates chronic graft-versus-host disease; CSP, cyclo
mycophenolate mofeti1.apamycin administration. PSE was continued at the a
B&MTose prescribed just before rapamycin was begun. In
n attempt to minimize corticosteroid use, tapering of
mmunosuppression began with PSE as early as 2
eeks after rapamycin was initiated if patients had
vidence of a clinical response. If patients had a con-
inued response, PSE was tapered off, followed by
alcineurin inhibitors and then rapamycin. The ulti-
ate taper schedule, however, was at the discretion of
he primary treating physician.
upportive Care
All patients received prophylaxis for Pneumocystis
arinii pneumonia while they were receiving immuno-
uppressive therapy.
valuations
Patients were monitored for changes in cGVHD,
dverse organ function, and opportunistic infections.
hysical examinations, blood chemistries, complete
lood counts with differential, fasting lipid panels,
erum immunoglobulins, and trough CSP, FK506,
tics
rs
Months of
cGVHD
before
Rapamycin Prior cGVHD Therapy
Prior
Maximum
PSE
Dose
mg/kg/d
43 1st, CSP/PSE; 2nd, clofazimine 0.8
1.5 1st, CSP/PSE 0.5
12 1st, CSP; 2nd, CSP/PSE 1
13 1st, CSP/PSE 0.34
22 1st, CSP/PSE; 2nd, clofazimine 0.17
12 1st, CSP/PSE 0.3
9 1st, CSP/PSE 0.08
3 1st, CSP/PSE 0.5
1 1st, FK/PSE; 2nd, MMF 1
9 1st, CSP/PSE 0.32
5 1st, CSP/PSE; 2nd, FK/PSE; 3rd,
clofazimine
0.2
3 1st, CSP/MMF/PSE 0.1
16 1st, CSP/PSE 0.19
HD 60 1st, CSP/PSE; 2nd, FK/PSE; 3rd,
MMF; 4th, clofazimine
0.3
3 1st, CSP/PSE
108 1st, CSP/PSE; 2nd,
PSE/clofazimine
Unknown
1 1st, CSP/PSE 0.67
16 1st, FK/PSE; 2nd, clofazimine 0.4
22 1st, CSP/PSE 0.36
; PSE, prednisone; FK, FK506; FTT, failure to thrive; mmF,racteris
ic Facto
skin
skin,
sive
skin
skin
skin
e cGV
skin
skin
sporinend/or rapamycin levels were obtained at routine in-
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5ervals during rapamycin administration. Selected
tudies, such as pulmonary function tests, tissue biop-
ies, or Schirmer tests, were repeated as clinically
ndicated. Rapamycin-related toxicity was graded ac-
ording to published criteria [21] and the National
ancer Institute common toxicity criteria (NCICTC).
ose modiﬁcations of rapamycin were planned begin-
ing with a 50% reduction of drug with renal insuf-
ciency (creatinine 2.0 mg/dL), thrombocytopenia
platelets75 000/L), neutropenia (absolute neutro-
hil count 1500/L), hypertriglyceridemia (triglyc-
rides600 mg/dL), hypercholesterolemia (total cho-
esterol 450 mg/dL), or other untoward toxicities.
urther reduction or discontinuation of rapamycin
ccurred if the toxicity did not resolve or if more
evere toxicities, such as hemolytic uremic syndrome
HUS), occurred. A diagnosis of HUS was based on
ndings of microangiopathic hemolytic anemia, in-
reased lactate dehydrogenase, renal insufﬁciency,
hrombocytopenia, and normal prothrombin and par-
ial prothrombin times.
Responses were deﬁned by clinical criteria and the
ack of a need for alternative immunosuppressive ther-
py. Complete response (CR) was deﬁned as complete
esolution of cGVHD, and partial response was de-
ned as an improvement in symptoms. No response
as deﬁned as a lack of improvement or progression
f cGVHD in a prior or new site. Follow-up was
alculated from the date of beginning rapamycin to
he last known follow-up date or the date of death.
he ﬁnal date of analysis was August 11, 2004.
tatistical Considerations
The primary objective of this trial was to evaluate
he clinical activity of sirolimus in combination with
SP or FK506 and corticosteroids as treatment for
teroid-refractory cGVHD. The primary end point
as clinical response in cGVHD. Secondary objec-
ives included determining the safety of this drug
ombination and its ability to reduce corticosteroid
se in the treatment of steroid-refractory cGVHD
atients.
The study was originally designed to enroll 30
atients. Plans were in place for early study ter-
ination if there was evidence of safety concerns, that
s, a true incidence of grade 3 to 4 toxicity exceeding
0%.
ESULTS
dverse Events
Nineteen patients began treatment with rapamy-
in in combination with calcineurin inhibitors and
SE. Nine patients discontinued rapamycin after a
edian of 4 months (range, 1-9 months) because of
dverse events (n  7) or noncompliance/patient re- h
0uest (n  2). Seven of 19 patients developed grade 3
r 4 toxicity according to the NCICTC—a true inci-
ence of 37%. The study was closed to accrual early
ecause of the grade 3 or 4 NCICTC toxicity inci-
ence of 30%. Table 3 summarizes the toxicity seen
n all patients, as well as the drug dose modiﬁcations
ade.
Renal insufﬁciency was a common adverse event
hat resolved or improved in most patients with either
emoval or a reduction in the dose of rapamycin. Two
atients had renal insufﬁciency and thrombocytopenia
n the setting of HUS. HUS was diagnosed in associ-
tion with CSP and rapamycin. Both patients had
omplete resolution of HUS after a course of plasma-
heresis and discontinuation of rapamycin and CSP.
ighteen infections occurred in 14 patients. The most
ommon infection was reactivation of herpes simplex
virus. One patient had cryptosporidium of the gas-
rointestinal tract, salmonella gastroenteritis, and a
acteroides fragilis perirectal abscess simultaneously.
he respiratory infections were bacterial pneumonia
n  4), bronchitis or sinusitis (n  2), and inﬂuenza
(n  2).
linical Outcome
Seventeen of 19 patients enrolled in the study are
live with a median follow-up from the beginning of
apamycin of 42 months (range, 31 to 61 months).
ixteen of nineteen patients were evaluable for re-
ponse. Two patients were inevaluable because of se-
ere toxicity occurring within 1 month of beginning
apamycin, and 1 patient was inevaluable because of
nreliable compliance. Fifteen of the 16 evaluable
atients had an initial clinical response, but 5 required
ithdrawal of rapamycin because of toxicity, as sum-
arized previously and in Table 3. Ten patients tol-
rated continuation of rapamycin for a median of 20
onths (range, 5 to 46 months), and 9 were alive a
edian of 44 months (range, 36 to 61 months) after
eginning rapamycin. Of the patients who continued
apamycin, 5 had received rapamycin as second-line
GVHD therapy and 5 as third-line cGVHD therapy.
he responses and outcomes of all 19 patients are
ummarized in Tables 4 and 5.
Four of the 10 patients who received continued
apamycin therapy required alternate therapy because
f progressive cGVHD after tapering immunosup-
ression or a stable partial response. The alternate
herapies began at 7, 21, 23, and 24 months after the
nitiation of rapamycin and included extracorporeal
hotopheresis or mycophenolate mofetil. Two of the
atients continued rapamycin while receiving alter-
ate therapy. Six patients have not required additional
herapy; however, 3 of these 6 patients had progressive
r recurrent cGVHD after PSE taper. One patient
ad been off PSE for 7 months when he developed
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Becurrent cGVHD and had a prompt CR after rein-
titution of PSE. The second patient had discontinued
SE and rapamycin while maintaining low-dose CSP
hen he developed new and progressive cGVHD
ymptoms. He responded to resumption of PSE and
n increased CSP dose. The third patient had pro-
ressive cGVHD during a taper of PSE that also
esponded to an increase in the PSE dose. This patient
ubsequently died of congestive heart failure while on
apamycin for 19 months. Three patients have had
ontinued CR with successful tapering of immunosup-
ression. Two of the 3 are off all immunosuppression,
nd the third is tapering PSE, rapamycin, and CSP.
he median time to discontinuation of PSE was 4
onths (range, 2-13 months) after beginning rapamy-
in. Of the 17 living patients, the 9 patients who
ontinued rapamycin have maintained a Karnofsky
erformance status of 80%, and the patients who
equired withdrawal of rapamycin have maintained
able 3. Toxicity and Drug Levels
Rapamycin
Continued
Patient
No.
CSP/FK
Level
(ng/mL)
Rapamycin
Level (ng/mL)
Maxi
Crea
(mg
es 1023 NA NA 1
es 2137 NA NA 1
es 1874 100-300 13 1
es
First trial 2038 100 14.4 2
Second trial 190-348 3.4-4.1 2
es 1834 Median 134 Median 12.7 2
es 2090 Median 160 Median 15.4 1
es 1760 200-683 Median 18.5 2
Median 100 10 2
es 2140 100-200 5 to 16 2
es 2152 NA NA 1
es 2189 <100 Median 13.5 0
o 2185 116-626 7.5-8 3
o 2225 72-335 Median 14.8 1
o 1578 125-137 10.5-17.8 2
o 1167 <5 Median 23.5 2
4
o 2113 200-350 Median 19.2 2
3
o 281 NA NA 2
o 2250 264 28-30.6 2
o 2069 NA NA
o 2067 59 33.7 2
SP indicates cyclosporin; FK, FK506; NCICTC, National Cance
insufﬁciency; HSV, herpes simplex virus; CR, chronic renal insu
GI, gastrointestinal; NE, not evaluated; heme, hematologic.Karnofsky performance status of 70%. 
B&MTapamycin and Calcineurin Inhibitor Blood Levels
Several patients did not have routine rapamycin or
alcineurin trough levels measured. Difﬁculty in obtain-
ng routinely timed drug levels in our patients often
ccurred because patients required laboratory testing
hrough outside facilities that frequently did not offer the
at that time) novel monitoring of trough rapamycin
evels. The available rapamycin and calcineurin inhibitor
rough levels are summarized in Table 3. The levels are
xpressed as a median in patients who had 4 separate
easurements over time. Roughly, in the 10 patients on
ontinued therapy, the steady-state rapamycin trough
evels ranged from 2 to 26 ng/mL, the steady-state
rough levels of CSP ranged from 40 to 400 ng/mL, and
he steady-state trough levels of FK506 ranged from 2 to
0 ng/mL. In the patients taken off rapamycin, the rapa-
ycin levels ranged from 2 to 55 ng/mL, CSP levels
anged from 59 to 626 ng/mL, and FK506 levels were
% Rapamycin
Reduced Toxicities or Events
Maximum
NCICTC Grade
80% ARI, thrombocytopenia Renal 1, heme 3
Myalgias Muscle 1
None
HSV-1 ARI,
thrombocytopenia
Infection 3,
renal 2, heme
2, renal 1
85% None
None
Gastritis, HSV-1 Renal 1
CRI Renal 2
50% Rapamycin/
CSP
ARI Renal 1
None
Hypertriglyceridemia,
HSV-1
Metabolic 3
Stopped ARI/HSV-1 Heme 3, renal 2
Stopped Headache, patient
requested removal
Headache 2
Stopped HUS Renal 3, heme 4
40% Stopped ARI, multiple GI
infections, bacterial
abscess
Infection 3,
renal 3
50% Stopped ARI, thrombocytopenia Renal 2, heme 2
Stopped Noncompliant NE
50% Stopped HUS, disseminated
VZV, oral/esophageal
HSV
Heme 4,
infection 3
Stopped Relapsed leukemia NE
Stopped ARI Heme 1, renal 1
tute common toxicity criteria; NA, not available; ARI, acute renal
cy; VZV, varicella-zoster virus; HUS, hemolytic uremic syndrome;mum
tinine
/dL)
.9
.7
.8
.6
.9
.4
.2
.7
.4
.4
.7
.1
.7
.5
.4
.3
.4
r Insti
fﬁcien5 ng/mL.
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5ISCUSSION
Rapamycin in combination with calcineurin inhib-
tors and PSE has activity in the salvage treatment of
GVHD. In this trial, 15 of 16 evaluable patients had
clinical response to this regimen. Unfortunately, a
igniﬁcant number of originally enrolled patients re-
uired discontinuation of rapamycin because of toxic-
ty. The 10 patients who tolerated rapamycin did not
equire additional therapy, and 3 of the 10 had a
rolonged continued response or stability of cGVHD
able 4. Responses and Outcomes of Patients Continuing Rapamycin
Patient
No. Response
Time to PSE
Discontinuation
after Day 1
Rapamycin
Months on
Rapamycin
1023 CR liver, PR skin,
oral
4 mo 35
2137 PR skin, oral; PD off
therapy
13 mo 15
1874 CR all sites;
scleroderma with
taper
On PSE 45
2038 CR liver; PR oral;
PD off rapamycin
7 mo; PSE
resumed after
24 mo
16
1834 CR liver; PR mouth/
eye; PD off PSE
4 mo, PSE
resumed after
7 mo
46
2090 CR skin and oral; PR
vaginal; new
ocular off
medication
3 mo 18
1760 Stable; PD off PSE 2 mo 21
2140 PR skin, oral, eye; PD
with taper
On PSE 19
2152 CR liver 10 mo 5
2189 CR oral, eye, vaginal,
skin On PSE
37
SE indicates prednisone; KPS, Karnofsky performance status; CR
nolate mofetil; PD, progressive disease; ECPP, extracorporeal p
able 5. Outcome of Patients Removed from Rapamycin
Patient
No. Response Cause of Drug Remo
2185 PR oral ARI/HSV-1
2225 PR oral Headache; patient
requested drug remo
1578 Inevaluable HUS
1167 PR skin; stopped PSE ARI/infection
2113 PR skin; tapered PSE ARI, thrombocytopenia
281 Inevaluable Noncompliant
2250 PR skin; tapered PSE HUS, disseminated VZ
oral/esophageal HSV
2069 NR Relapsed leukemia
2067 Inevaluable ARI
PS indicates Karnofsky performance status; PR, partial response; A
uremic syndrome; VZV, varicella-zoster virus; AML, acute myeloid le
2hile tapering all immunosuppression. With a median
ime from beginning rapamycin of 3.5 years, 2 pa-
ients are taking no immunosuppression and have a
R of cGVHD. The number of patients successfully
ff cGVHD therapy at this point is disappointing but
ot unexpected in this clinically challenging group of
atients. Prior experience shows the outcome of sal-
age therapy for cGVHD to be that30% of patients
ay successfully discontinue all immunosuppression
ithin 2 to 3 years of requiring salvage treatment for
ew
rapy,
from
1
mycin
Months
Follow-up
Therapy Status at
Last Follow-up
KPS Day 0
Rapamycin
KPS
Current
3 mo 61 FK and MMF 80% 100%
1 mo 52 ECPP, PSE,
FK506, and
rapamycin
70% 80%
4 m 45 PSE, rapamycin
and MMF taper
80% 100%
45 PSE, and CSP 70% 90%
46 PSE taper; stable
rapamycin/CSP
80% 90%
44 No medication 90% 100%
mo 37 ECPP 90% 100%
19 Rapamycin, CSP,
and PSE taper
70% 0%, died
CHF
36 No medication 90% 100%
37 CSP, PSE, and
rapamycin taper
80% 100%
lete response; PR, partial response; FK, FK506; MMF, mycophe-
eresis; CSP, cyclosporine; CHF, congestive heart failure.
Months on
Rapamycin
Months of
Follow-up
KPS
Initial
KPS
Current
2 43 70% 80%
4 41 80% 100%
1 42 70% 90%
9 31 80% 80%
4 42 90% 100%
8 41 70% 70%
3 35 90% 70%
4 5 (death of
AML)
70% 0%
1 31 80% 80%
te renal insufﬁciency; HSV, herpes simplex virus; HUS, hemolyticN
The
Time
D
Rapa
Yes, 2
Yes, 2
Yes, 2
No
No
No
Yes, 7
No
No
No
, compval
val
V,
RI, acu
ukemia; PSE, prednisone; NR, not reported.
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Rapamycin and Chronic GVHD
BGVHD [22,23]. The overall survival (OS) at 2 to 3
ears after beginning salvage therapy for cGVHD in
elected clinical trials ranges from 64% to 81% [22-
4]. A trial reported in abstract form showed an OS of
2% in 29 patients treated with rapamycin and FK506
s salvage therapy for cGVHD despite an overall re-
ponse rate of 68% [25]. In comparison, 17 (89%) of
he 19 patients originally enrolled in our trial are alive,
ith 1 death due to relapsed malignancy and 1 due to
ongestive heart failure at a median follow-up of 3
ears. Eighteen of the 19 patients in our trial had 0
isk factors or 1 risk factor based on the prognostic
odel for cGVHD patients described by Akpek et al.
5], which correlates with the predicted 5-year OS of
1% in patients with 0 risk factors or 1 risk factor.
In addition to determining the efﬁcacy of rapamy-
in in combination with calcineurin inhibitors and
SE, we attempted to reduce the use of corticoste-
oids in the treatment of cGVHD. Early withdrawal
f corticosteroids was not successful in our patients.
atients who required alternate therapy of cGVHD
id so after a prolonged period off or tapering PSE,
nd other patients required reinstitution or resump-
ion of prior doses of PSE to regain a previously
ocumented clinical response. More successful re-
oval of PSE may be achieved with delayed complete
ithdrawal of PSE and the concomitant immunosup-
ression.
The sites of organ toxicity in this phase II
GVHD trial of rapamycin in combination with cal-
ineurin inhibitors and PSE are similar to the solid
rgan transplant experience. The severity and fre-
uency of speciﬁc organ dysfunction, however, does
eem to vary. The most common toxicities in the renal
ransplant clinical trials were hyperlipidemias and cy-
openias, which occurred in as many as 40% and 61%
f patients, respectively [17,26-28]. Hyperlipidemia
nd cytopenia were infrequent and not prohibitive in
ur patients. The most profound instance of throm-
ocytopenia resolved with a decrease in the dose of
apamycin. Only 1 patient required lipid-decreasing
gents during rapamycin therapy. The most marked
iscrepancy in toxicity between our cGVHD patients
nd the renal transplant patient population was the
ncidence and severity of nephrotoxicity. Nearly half
f the treated patients in our trial could not continue
apamycin, most notably because of renal insufﬁciency
nd HUS. A report of rapamycin therapy in 21 ste-
oid-refractory aGVHD patients also describes limit-
ng toxicity with evidence of HUS in 5 patients and
eizures in 2 patients [29]. Hyperlipidemia and cyto-
enias were common in this aGVHD study: 4 patients
iscontinued rapamycin because of toxicity alone.
In renal transplant rat models, rapamycin therapy
lone was not associated with nephrotoxicity or a
eduction in glomerular ﬁltration rate or renal blood
ow, unlike therapy with CSP or FK506 [30,31]. In G
B&MTenal transplant patients, phase III trials comparing
ingle doses of rapamycin [32] or rapamycin- versus
SP-based therapy conﬁrmed that rapamycin did not
educe the glomerular ﬁltration rate or cause nephro-
oxicity [33,34]. In addition, psoriatic patients receiv-
ng chronic single therapy of rapamycin did not have
ltered baseline renal function [35]. However, in the
ost relevant randomized trials of rapamycin used in
ombination with CSP for the prevention of organ
ejection in renal transplant patients, there was a sig-
iﬁcant reduction in glomerular ﬁltration rate and an
ncrease in serum creatinine in the rapamycin/CSP
reatment arm compared with the CSP/azathioprine
r the CSP/placebo treatment arms [19,20]. This ra-
amycin-related nephrotoxicity is thought to be due
o the potentiation of calcineurin-induced renal tox-
city; this concept is supported by animal studies [36].
In the human renal transplant literature, there has
een an association between organ toxicity and higher
evels of rapamycin and CSP [17,27,37]. The previ-
usly quoted trial of rapamycin for the treatment of
teroid-refractory aGVHD reported rapamycin levels
anging from 17 to 19 ng/mL at day 7 and 20 to
5 ng/mL at day 14 of rapamycin therapy [29]. Al-
hough higher rapamycin and calcineurin trough lev-
ls may roughly correlate with the renal and hemato-
ogic toxicities seen in our trial, the unfortunate
nconsistent monitoring of the drug levels limits our
bility to make a deﬁnitive statement regarding drug
evels and toxicity. Of interest, a recently reported
hase II trial used rapamycin, FK506, and methotrex-
te for GVHD prophylaxis in unrelated donor HCT,
herein relatively low levels of FK506 (5-10 ng/mL)
nd rapamycin (3-12 ng/mL) were targeted [38]. Min-
mal rapamycin and FK506-related toxicities were
een without an apparent sacriﬁce in aGVHD inci-
ence. The relatively high drug levels observed in the
ormer aGVHD treatment trial and in our study may
ave contributed to the untoward toxicity described.
igher drug levels may also explain the apparent po-
entiation of renal toxicity with the combination of
alcineurin inhibitors and rapamycin as the most
rominent limitation to the continued treatment of
apamycin in our patients. In fact, recent recommen-
ations for trough drug levels in the subacute phase
fter renal transplantation—that is, 3 months after
ransplantation—are rapamycin 10 ng/mL and CSP
00 ng/mL [39].
Clearly, our pilot study in cGVHD illustrates the
mportance of knowing the drug interactions and their
oxicities when exploring combination therapies such as
alcineurin inhibitors, rapamycin, and corticosteroids.
owever, despite the adverse events seen in this treat-
ent-refractory group of cGVHD patients, there were
eﬁnite responders, with some patients attaining an ex-
ellent response without treatment-related mortality.
iven that this trial suffered marked attrition because of
53
r
m
i
t
c
t
p
b
o
A
R
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
L. J. Johnston et al.
5enal toxicity, the use of rapamycin in cGVHD may be
ore feasible in conjunction with less conventional dos-
ng of calcineurin inhibitors and more rigorous moni-
oring of rapamycin blood levels. In addition, tapering
orticosteroids over a longer period of time may prevent
he loss of response seen in several initially responding
atients. With this alternate approach, one may gain the
eneﬁt of the synergy and alternate mechanism of action
f rapamycin with less prohibitive toxicity.
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